|Grant Number:||5U01CA152926-03 Interpret this number|
|Primary Investigator:||Hur, Chin|
|Organization:||Massachusetts General Hospital|
|Project Title:||Controlling Esophageal Cancer in the Us.: a Colloraborative Modeling Project|
DESCRIPTION (provided by applicant): The ultimate goal of the proposed research project is to advance our understanding of esophageal cancer and the impact of cancer control interventions in order to diminish the burden of this disease. We will accomplish this goal through a collaborative and comparative modeling project. The incidence of esophageal adenocarcinoma (EAC) has been rising at an alarming rate over the past three decades. Although the absolute number of EAC cases per year remains too low to screen the general population, targeted screening may be appropriate. Heartburn, the primary symptom of gastroesophageal reflux disease (GERD), affects 60 million Americans and can lead to Barrett's esophagus (BE), a premalignant condition associated with the greatest risk (30-125x) of developing EAC. Because of the significant number of individuals affected with GERD and BE, the management of these patients has become a public health issue. However, an accepted screening or surveillance program for EAC has not been proposed. The goal of National Cancer Institute's (NCI) Cancer Intervention and Surveillance Modeling Network (CISNET), and a broader theme for our research proposal, is to bring together different simulation models, embracing differences in model structure to improve the overall understanding of a cancer's natural history and to improve model projections. Our application is in response to CISNET's recent expansion to include esophageal cancer as one of the targeted cancers within its network. As a new cancer group, we have the distinctive opportunity to perform groundbreaking analyses and to provide the crucial evidence synthesis that are urgently needed and novel. Our innovative collaboration will perform comparative modeling that focuses on, but is not limited to, determining the effectiveness of clinically relevant issues in esophageal cancer, multiscale modeling and incorporation of biomarkers, and the creation and dissemination of an interactive policy level decision tool. The investigators and the institutions assembled for this project have expertise in all facets of simulation disease modeling, clinical aspects of esophageal cancer, and a proven history of research and collaborations, providing assurance that the project's goals will be achieved in this rich environment. The research will address the overarching goals of increasing our understanding of the natural history of esophageal cancer and determining the impact and of potential cancer control interventions with the ultimate goal of ameliorating cancer morbidity.
The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions.
Authors: Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M
Source: Med Decis Making, 2014 Oct 2;null, p. null.
EPub date: 2014 Oct 2.
Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.
Authors: Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG
Source: Cancer Epidemiol Biomarkers Prev, 2014 Jun;23(6), p. 997-1006.
EPub date: 2014 Apr 1.
Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus.
Authors: Yasuda K, Choi SE, Nishioka NS, Rattner DW, Puricelli WP, Tramontano AC, Kitano S, Hur C
Source: Dig Dis Sci, 2014 Jul;59(7), p. 1560-6.
EPub date: 2014 Jan 7.
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Authors: Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C
Source: Cancer Prev Res (Phila), 2014 Mar;7(3), p. 341-50.
EPub date: 2013 Dec 31.
Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands.
Authors: Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, AragonÚs N, van Ballegooijen M, Inadomi JM
Source: Am J Gastroenterol, 2014 Mar;109(3), p. 336-43; quiz 335, 344.
EPub date: 2013 Dec 17.
Trends in esophageal adenocarcinoma incidence and mortality.
Authors: Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ
Source: Cancer, 2013 Mar 15;119(6), p. 1149-58.
EPub date: 2012 Dec 11.
Impact of tumor progression on cancer incidence curves.
Authors: Luebeck EG, Curtius K, Jeon J, Hazelton WD
Source: Cancer Res, 2013 Feb 1;73(3), p. 1086-96.
EPub date: 2012 Oct 10.
The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
Authors: Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM
Source: Gastroenterology, 2012 Sep;143(3), p. 567-75.
EPub date: 2012 May 21.
Screening and surveillance for Barrett's esophagus: current issues and future directions.
Authors: Choi SE, Hur C
Source: Curr Opin Gastroenterol, 2012 Jul;28(4), p. 377-81.
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis.
Authors: Omer ZB, Ananthakrishnan AN, Nattinger KJ, Cole EB, Lin JJ, Kong CY, Hur C
Source: Clin Gastroenterol Hepatol, 2012 Jul;10(7), p. 722-7.
EPub date: 2012 Mar 15.
Biomarker-based early cancer detection: is it achievable?
Authors: Hazelton WD, Luebeck EG
Source: Sci Transl Med, 2011 Nov 16;3(109), p. 109fs9.
The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model.
Authors: Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C
Source: Cancer Epidemiol Biomarkers Prev, 2011 Nov;20(11), p. 2450-6.
EPub date: 2011 Sep 19.